DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Key Pharma News Issue 50" report to their offering.
Ownership Of Digital Reputation Crucial With Growing Compassionate Use Demand
As companies target ever rarer diseases with no real therapeutic options and patient groups become more empowered, compassionate use programmes will continue to rise. The increase in US compassionate use approvals represents a great opportunity for digitally astute companies, but for those without a firm grip on their digital reputation, the risks are great. Greater access to experimental drugs in a digital world allows information about brands to be disseminated quickly. In order to ensure that they remain the authority on their products and the masters of their own digital image, companies must ensure high levels of stakeholder engagement though digital platforms, particularly social media. Failure to take ownership could allow negative perceptions to run unmitigated.
Key Topics Covered:
1. Agreements
- GSK Making Gains In Customising Novel Oncology Division
- MedinCell/Sandoz Collaborate To Develop Long-Acting Injectable Products
2. Corporate Activity
- Gilead To Target Transformational Opportunities
- AstraZeneca Completes Majority Equity Stake Purchase Of Acerta
- Oncology Performance Validates Strong Focus
- Market Conditions Challenge Sandoz But Biosimilars Provide Optimism
- Growing Strength Of Roche's Immunology Division Underlined By FY15 Results
- NGS Portfolio Development To Benefit Diagnostics And Pharmaceuticals
- Diversification Key To Overcoming Tecfidera Reliance
- Successful Integration And Restructuring Essential For Lannett's Future Prospects
3. Product News
- Cabozantinib Will Encounter Toughening Market Environment Despite Swift Entry
- Tagrisso Approved In EU
- FDA Approves Merck's Fixed-Dose HCV Regimen
- Health Canada Approves Vertex' Orkambi To Treat CF Patients
- FDA Approves Takeda's Dexilant SoluTab
- Sun Launches Imatinib Mesylate In US
- Breakthrough Designation For Rapastinel Enhances Competitive Position
- Gilead In Strong Position To Counter TAF Lawsuit
- Health Canada Approves Haemophilia Treatment, Kovaltry
- CMS Biosimilar Reimbursement Rule Highlights Need For Interchangeability Guidance
- FDA Budget Request Takes Aim At Pay-For-Delay Agreements
- Pfizer Edges Towards US Biosimilar Infliximab Dominance
4. R&D
- Combination Approach Increases Commercial Scope For Small Oncolytic Immunotherapy Developers
- Direct Jakafi Competition Prospects In Myelofibrosis Waning
- Digital Healthcare Partnerships Offer Expedited Development Potential
- Positive Top-Line Results Announced In Repatha Phase III GAUSS-3 Trial
For more information visit http://www.researchandmarkets.com/research/xfxlmn/key_pharma_news
